News & Publications

Keep up with our progress

Updates on the latest news, research and collaborations emerging from IBRI.

Newsroom

01/29/2026 Libris Innovations Welcomes Ramani Varanasi as Chief Executive Officer Read more Press Release 01/26/2026 Indiana Biosciences Research Institute Launches Life Science Lab Podcast Read more Press Release 01/08/2026 Indiana Biosciences Research Institute Launches New Website to Further Advance Its Mission Read more Press Release 11/17/2025 Indiana Biosciences Research Institute Announces Research Partnership with Eli Lilly and Company Read more Press Release 10/29/2025 Indiana Biosciences Research Institute Keeps MBX Biosciences Growing in Indiana Read more Press Release 10/14/2025 Indiana Biosciences Research Institute Welcomes Dr. Ari Landon as Chief Scientific Business Development Officer Read more

Podcasts

02/16/2026 Life Science Lab: Ramani Varanasi, MS, MBA, CEO of Libris Innovations In this episode of Life Science Lab, host Christopher Conway, Chief Philanthropy Officer and Executive Vice President of Strategic Communications at the Indiana Biosciences Research Institute (IBRI), talks with Ramani Varanasi, CEO of Libris Innovations, the for-profit subsidiary of the IBRI. They discuss how IBRI’s research engine and Libris Innovations’ venture creation efforts work hand in hand to advance scientific discoveries toward commercialization and patient impact. Ramani also shares her perspective on the biotech investment climate, Indianapolis’ growing life sciences ecosystem, and her early priorities for Libris Innovations. Listen now 01/22/2026 Life Science Lab: Alan Palkowitz, PhD, President and CEO of IBRI In the first episode of Life Science Lab, host Ari Landon, PhD, sits down with Alan Palkowitz, PhD, President and CEO of the Indiana Biosciences Research Institute (IBRI), to discuss how the IBRI is accelerating translational research and advancing new therapies through collaboration across the life sciences ecosystem. They explore what makes the IBRI model unique, the institute's scientific priorities, and what it takes to move discoveries toward real-world impact. Listen now

Annual Reports

2022 Annual Report Read more 2021 Annual Report Read more 2020 Annual Report Read more 2019 Annual Report Read more 2018 Annual Report Read more 2017 Annual Report Read more 2016 Annual Report Read more

Publications & Presentations

02/01/2024 Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2 Read more 01/11/2024 RIPK3 promotes islet amyloid-induced ß-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes Read more 01/03/2024 Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric P13Ka inhibitor that decouples antitumor activity from hyperinsulinemia Read more 10/05/2023 Which small molecule? Selecting chemical probes for use in cancer research and target validation Read more 07/05/2023 Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes Read more 11/22/2022 Therapeutic strategies targeting pancreatic islet beta-cell proliferation, regeneration and replacement Read more

Keep me updated

Sign up for our newsletter to stay updated on IBRI’s progress.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name
Explore our pipeline